Innate Pharma SA
XBER:IDD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Innate Pharma SA
XBER:IDD
|
FR |
|
R
|
ReeVo SpA
F:4PX
|
IT |
|
C
|
CombinedX AB (publ)
F:K13
|
SE |
|
Dynamatic Technologies Ltd
NSE:DYNAMATECH
|
IN |
|
Akzo Nobel NV
F:AKUP
|
NL |
|
M
|
Millennium Cell Inc
OTC:MCELQ
|
US |
|
K
|
KT Submarine Co Ltd
KOSDAQ:060370
|
KR |
|
S
|
Sandfire Resources Ltd
F:S2Z
|
AU |
|
I
|
I Minerals Inc
XTSX:IMA
|
CA |
|
C
|
Carrefour SA
DUS:CAR
|
FR |
|
InspireMD Inc
NASDAQ:NSPR
|
IL |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
M
|
Milae Bioresources Co Ltd
KOSDAQ:218150
|
KR |
|
Vimian Group AB
F:0V0
|
SE |
|
P
|
Pushfor Tech Inc
F:713
|
CA |
|
Doubleview Gold Corp
F:1D4
|
CA |
|
B
|
Bioventus Inc
NASDAQ:BVS
|
US |
|
T
|
Toyota Industries Corp
XMUN:TAH
|
JP |
Bankruptcy Probability
Innate Pharma SA's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Innate Pharma SA Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| FR |
|
Innate Pharma SA
PAR:IPH
|
149.4m EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
443.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
211.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.8B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
132B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
53.5B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
81.2B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Innate Pharma SA's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Innate Pharma SA has total debt of 13.8m EUR. This includes both short-term (0 EUR) and long-term (13.8m EUR) debt.
You can find a full breakdown on its Balance Sheet.
